Using magnetic markers to locate breast cancer and lymph nodes after chemotherapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the feasibility of using magnetic seed localization for non-palpable breast cancer and targeted axillary dissection in patients with node-positive breast cancer following neoadjuvant chemotherapy. Eligible patients will have magnetic seeds placed in their breast tumor and lymph nodes before starting chemotherapy. After treatment, imaging assessments will guide surgical planning, allowing for breast-conserving surgery or mastectomy with targeted axillary dissection. The study aims to improve surgical outcomes and minimize unnecessary procedures.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* All patients with cT1-3N1 invasive ductal carcinoma planned for neoadjuvant chemotherapy and/or target therapy
* mentally competent to give informed consent
* Agreed to proceed with curative operation after chemotherapy and tentatively keen for breast conservative surgery and targeted axillary dissection after neoadjuvant chemotherapy
* Radiologically 1-3 ipsilateral axillary lymph node metastases confirmed by cytology or biopsy

Exclusion Criteria:

* Presence of distant metastasis, inflammatory breast cancers, multi-centric breast cancers
* History of previous ipsilateral axillary surgery or irradiation
* Hypersensitivity to dextran compounds or iron
* Iron overload disease
* Pregnant or lactating patients
* Patients with pacemaker or other implantable metallic devices in chest wall or prosthesis in shoulder
* Mentally incompetent patients

Where it's running

• University of Hong Kong
  Hong Kong, Hong Kong Recruiting

Study contacts

• Study coordinator: Chi Mei Vivian Man, FCSHK, FRCSEd
• Email: vivian27@hku.hk
• Phone: 852-25898116

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Adding silibinin to standard daunorubicin or idarubicin therapy for newly diagnosed non‑M3 acute myeloid leukemia

  This trial will test whether adding silibinin (a liver‑protecting compound) to standard daunorubicin or idarubicin chemotherapy helps people with newly diagnosed non‑M3 acute myeloid leukemia.

  Recruiting Phase 4 Fujian Medical University Union Hospital · Fuzhou, Fujian · NCT07561892

• AI-powered mobile app to support chemotherapy for breast cancer

  A mobile app in Arabic uses AI to help women undergoing chemotherapy see if it can improve symptom control and medication adherence compared with standard care.

  Recruiting University of Baghdad · Baghdad · NCT07273812

• Camrelizumab plus apatinib with or without FOLFOX chemotherapy for advanced liver cancer

  This research will test whether adding FOLFOX chemotherapy to camrelizumab plus apatinib helps adults with advanced hepatocellular carcinoma who have not received prior systemic treatment.

  Recruiting Phase 3 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07267806

• Personalized management for borderline resectable and locally advanced pancreatic cancer

  This study is testing if giving chemotherapy first can help people with borderline resectable and locally advanced pancreatic cancer have surgery and improve their chances of survival.

  Recruiting Oslo University Hospital · Bergen, Norway and 4 other locations · NCT06944587

• Impact of massage therapy on sleep in young cancer patients

  This study is testing whether personalized massage therapy can help young cancer patients in the hospital sleep better and feel less tired, anxious, and in pain during their treatment.

  Recruiting Children's Hospital of Philadelphia · Washington D.C., District of Columbia and 1 other locations · NCT06892158

• Cryoablation for small breast tumors (SIX)

  This study will test whether cryoablation works as well as standard breast surgery for people with small (≤2.0 cm), unifocal early-stage breast cancer and will compare direct costs over one year.

  Recruiting Phase 3 Hospital do Coracao · São Paulo, São Paulo and 1 other locations · NCT06839001

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.